Almirall is a specialty pharmaceutical company with a strong focus on medical dermatology. It develops and markets prescription treatments for skin conditions such as psoriasis, acne and actinic keratosis, alongside selected other therapeutic areas. The company combines in-house R&D with licensed products and serves dermatologists and patients primarily in Europe and other selected international markets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 274.4 | — | 5 | — |
| Q3 2025 | 260.2 | — | 12.5 | — |
| Q4 2025 | 547.6 | — | 19.6 | — |
| Q1 2026 | 292.4 | — | 15.3 | — |
| Q2 2026 | 310.3 | 13.1% | 24.3 | 387.1% |
All markets — KeepWinning global stock screener
Other companies on Bolsa de Madrid: Meliá Hotels International, S.A. (MEL), Distribuidora Internacional de Alimentación, S.A. (DIA), Técnicas Reunidas, S.A. (TRE), DIGI Spain Telecom, S.A. (DIGIS), HBX Group International plc (HBX), Inmocemento, S.A. (IMC)